Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain CORT message board posts where the ticker symbol CORT has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest CORT SEC Filings

Filings Format Description Filing Date File/Film Number
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-20-014630 Size: 5 KB
2020-05-29
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-20-014629 Size: 5 KB
2020-05-29
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-20-014628 Size: 5 KB
2020-05-29
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-20-014627 Size: 5 KB
2020-05-29
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-20-014622 Size: 5 KB
2020-05-29
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001225208-20-008345 Size: 12 KB
2020-05-29
8-K  Documents   Interactive Data Current report, item 5.07
Acc-no: 0001628280-20-008606 (34 Act)  Size: 201 KB
2020-05-29 000-50679
20926708
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-20-014352 Size: 8 KB
2020-05-27
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-20-014349 Size: 7 KB
2020-05-27
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001628280-20-006270 (34 Act)  Size: 4 MB
2020-05-04 000-50679
20845765
More CORT SEC Filings


Related news from
Mon, 06 Jul 2020
16:56:32 +0000
Is Corcept Therapeutics Incorporated's(NASDAQ:CORT) Recent Stock Performance Tethered To Its Strong Fundamentals?
Corcept Therapeutics''s (NASDAQ:CORT) stock is up by a considerable 49% over the past three months. Given that the...
Wed, 01 Jul 2020
14:47:02 +0000
Corcept Begins Enrollment in Phase III Pancreatic Cancer Study
Corcept (CORT) enrolls the first patient in the phase III RELIANT study on relacorilant in combination with Abraxane for treating metastatic pancreatic cancer.
Tue, 30 Jun 2020
20:05:10 +0000
Corcept Therapeutics Initiates Phase 3 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer
Corcept Therapeutics Incorporated (CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced enrollment of the first patient in RELIANT, an open-label, Phase 3 trial of relacorilant in combination with nab-paclitaxel (Celgene’s medication, Abraxane®) in patients with metastatic pancreatic cancer. “Metastatic pancreatic cancer is an aggressive disease and there is an urgent need for effective therapies,” said Andreas Grauer, MD, Corcept’s Chief Medical Officer. RELIANT has a planned enrollment of 80 patients with metastatic pancreatic cancer, with an interim analysis of data from the first 40 patients.
Fri, 19 Jun 2020
13:40:53 +0000
Hedge Funds Standing By Corcept Therapeutics Incorporated (CORT)
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]
Mon, 15 Jun 2020
12:30:10 +0000
Corcept Therapeutics to Present Data at the American Association of Cancer Research Annual Meeting
Corcept Therapeutics Incorporated (CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, will present novel genomic data from patients with adrenocortical carcinoma at the 2020 American Association of Cancer Research (AACR) Annual Meeting. Following its presentation, a copy of our poster will be available at the Research & Pipeline / Publications tab of our website. “Excessive cortisol in patients with adrenal cancer causes Cushing’s syndrome and may also blunt the efficacy of immunotherapeutic agents such as checkpoint inhibitors,” said Andreas Grauer, MD, Corcept’s Chief Medical Officer.
Tue, 09 Jun 2020
03:24:42 +0000
Edited Transcript of CORT earnings conference call or presentation 4-May-20 9:00pm GMT
Q1 2020 Corcept Therapeutics Inc Earnings Call
Wed, 03 Jun 2020
15:30:03 +0000
Has Corcept Therapeutics (CORT) Outpaced Other Medical Stocks This Year?
Is (CORT) Outperforming Other Medical Stocks This Year?
Wed, 03 Jun 2020
15:30:03 +0000
Why Is Corcept (CORT) Up 8.2% Since Last Earnings Report?
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Tue, 02 Jun 2020
14:00:28 +0000
These 4 Biotech Stocks Are Outperforming Their Peers — Here's Why
The best biotech companies to invest in tend to have a commonality: a strong streak of earnings growth.
Thu, 14 May 2020
20:05:10 +0000
Corcept Therapeutics to Present Data at the American Society of Clinical Oncology Annual Meeting
Corcept Therapeutics Incorporated (CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, will present novel immuno-oncology data from the selective cortisol receptor modulator relacorilant at the 2020 American Society of Clinical Oncology Annual Meeting. “Patients with adrenal cancer often have tumors that produce cortisol, which may limit the efficacy of immune checkpoint inhibitors,” said Andreas Grauer, MD, Corcept’s Chief Medical Officer. “Our hypothesis is that administering a selective cortisol modulator in combination with an immunotherapeutic agent such as pembrolizumab will treat the symptoms of hypercortisolism and help pembrolizumab achieve its maximum effect.1 The data presented in this abstract have informed the design of our Phase 1b trial in which 20-patients with metastatic or unresectable adrenal tumors that produce cortisol will receive our selective cortisol modulator relacorilant in addition to pembrolizumab.”
Wed, 13 May 2020
17:16:24 +0000
6 Stocks John Hussman Continues to Buy
AT&T; makes the list Continue reading...
Tue, 12 May 2020
11:45:00 +0000
Should You Climb on Board the Corcept Therapeutics Train?
Corcept Therapeutics Inc. (NASDAQ: CORT) continues to make its investors happy. The Menlo Park, Calif., biotech company beat earnings estimates in its first-quarter report last week. While the effects of the COVID-19 pandemic have led some companies to forgo guidance, Corcept reaffirmed its revenue estimates of $355 million to $375 million for the year.
Mon, 11 May 2020
02:46:10 +0000
Were Hedge Funds Right About Corcept Therapeutics Incorporated (CORT)?
Hedge funds don't get the respect they used to get. Nowadays investors prefer passive funds over actively managed funds. One thing they don't realize is that 100% of the passive funds didn't see the coronavirus recession coming, but a lot of hedge funds did. Even we published an article near the end of February and […]
Wed, 06 May 2020
22:27:00 +0000
Corcept Therapeutics Shows Rising Price Performance With Jump To 85 RS Rating
One stock that fits that bill is Corcept Therapeutics, which had its Relative Strength (RS) Rating upgraded from 77 to 85 Wednesday. Corcept Therapeutics is not currently offering a proper buying opportunity. Corcept Therapeutics saw both earnings and sales growth rise last quarter.
Tue, 05 May 2020
18:50:06 +0000
Corcept (CORT) Q1 Earnings Top Estimates, Revenues Rise Y/Y
Corcept's (CORT) earnings and revenues beat estimates in the first quarter of 2020. Solid adoption of the company's Cushing's syndrome drug, Korlym, drives sales.
Tue, 05 May 2020
12:31:12 +0000
New Strong Buy Stocks for May 5th
New Strong Buy Stocks for May 5th
Tue, 05 May 2020
05:02:01 +0000
Corcept Therapeutics Incorporated (CORT) Q1 2020 Earnings Call Transcript
CORT earnings call for the period ending March 31, 2020.
Mon, 04 May 2020
23:05:11 +0000
Corcept Therapeutics (CORT) Tops Q1 Earnings and Revenue Estimates
Corcept (CORT) delivered earnings and revenue surprises of 19.05% and 7.35%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Mon, 04 May 2020
20:05:10 +0000
Corcept Therapeutics Announces First Quarter 2020 Financial Results And Provides Corporate Update
MENLO PARK, Calif. , May 04, 2020 -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat.
Mon, 27 Apr 2020
20:05:10 +0000
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
MENLO PARK, Calif., April 27, 2020 -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "Since being one of the beginning members, it has been a great experience. This select group of sophisticated investors has exceptional knowledge to share. The members come from all walks of life and have varied experiences. Many are experts in finance and commodity related issues. Many are good money managers. This is a value oriented group where good yields on a variety of stocks are the main focus." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2020, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards